Actively Recruiting
Comparing Anticoagulants for Primary Hemostasis Testing Using PFA200 Platelet Function Analyzer
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-09-29
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring how different anticoagulants affect the platelet function analysis PFA test, which is used to study primary hemostasis and platelet interactions with von Willebrand factor. The study focuses on comparing results from the standard citrate anticoagulant with a new anticoagulant called BAPA, which may have less impact on blood platelets. This observational study is led by Centre Hospitalier Universitaire Dijon and includes patients needing a PFA test for diagnosing von Willebrand disease. Participants will have three additional BAPA tubes of blood collected at the same time as their routine PFA test sample. The BAPA anticoagulant works differently from citrate by blocking coagulation through another mechanism, and the study aims to compare the occlusion time measurements from both anticoagulants. No experimental treatments are given, as this study observes samples collected alongside regular clinical care. During the study, researchers will measure the occlusion time at baseline to assess platelet function. Participation involves providing blood samples during a scheduled hemostasis consultation. The study does not include any changes to usual care or treatments and does not involve long-term follow-up. The total participation time corresponds to the routine consultation and blood sampling visit.
CONDITIONS
Brief Title
Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)
Research Team
E
Emmanuel De Maistre
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here